Abcam, ab266730, Human TYK2 knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TYK2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TYK2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Tyrosine kinase 2 (TYK2) also known as JAK1B is a non-receptor tyrosine kinase that weighs approximately 134 kDa. It belongs to the Janus kinase (JAK) family which includes JAK1 JAK2 and JAK3. TYK2 is vital in signal transduction for several cytokine receptors. The expression of TYK2 occurs broadly in different tissues including immune system cells. It plays an important mechanical role in transferring signals from cell surface receptors to intracellular signaling pathways which modulates various physiological processes.
Biological function summary
TYK2 mediates intracellular signaling that affects both innate and adaptive immune responses. It associates with cytokine receptors forming functional complexes that are critical for initiating JAK-STAT signaling. This type of signaling is responsible for regulating gene expression after cytokine binding. TYK2 is known for interacting with Type I interferons and interleukin-10 family cytokines indicating its importance in immune regulation.
Pathways
TYK2 acts within the JAK-STAT pathway a fundamental signaling cascade triggered by various cytokines and growth factors. The JAK-STAT pathway includes key partners such as STAT1 STAT2 and STAT3 proteins which are phosphorylated by TYK2 to propagate signal transduction. Additionally TYK2 is involved in the 'intercept blocking buffer' mechanism that adjusts signal strength thereby ensuring appropriate cellular responses to external stimuli.
Altered TYK2 activity has associations with immune-related conditions like psoriasis and systemic lupus erythematosus. Dysregulation of TYK2 can lead to improper immune signaling which contributes to these autoimmune conditions. Furthermore TYK2 interacts with other Janus kinase family members including JAK1 and JAK3 which can influence its role in the pathogenesis of these diseases potentially offering targets for therapeutic intervention.